EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical and safety outcomes of conversion original tacrolimus to generic tacrolimus in Turkish kidney transplant recipients

Emrah Günay

Transplantation Reports · 2020-09 · 5 (3) · 100056

DOI: 10.1016/j.tpr.2020.100056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation Reports, 2020-09. Verfasst von Emrah Günay. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

After the United States, The Food and Drug Administration approved the use of the first generic of the original tacrolimus in 2009, generic tacrolimus was preferred in many countries for cost-reducing reasons. This is the first study on the conversion of original tacrolimus to the generic tacrolimus, reported from Turkey.

Methods

The inclusion criteria of this single-center, retrospective study were 1) being ≥18 years old, 2) passing at least three months after kidney transplantation, 3) conversion from reference tacrolimus (Prograf®) to generic tacrolimus (Adoport®). The primary endpoints were acute rejection, an increase in serum creatinine, decreases in e-GFR, tacrolimus level, tacrolimus concentration/dose ratio. We applied the paired T-test to analyze the pre-conversion and final visit laboratory values.

Results

Thirty-six patients who agreed to use generic tacrolimus evaluated. The mean age was 39.8 years (± 11.6), % 52,7 were female, % 86,1 were living donor transplants. The patients followed up for 12 months (3-41). There was no increase in serum creatinine value, no decreases in e-GFR and tacrolimus concentration/dose ratio. We observed a decrease in tacrolimus level (p=0,037). Decreasing the target value may have caused this result, as there are 9 patients with positive BK-DNA. None of the patients needed a biopsy.

Conclusion

Based on the results of our study, renal outcomes are safe and the drugs could be changed safely. Whether Prograf® or Adoport®, whichever is used, it is important to continue taking the drug at the recommended dose and time. The physician should be careful in dose adjustment after conversion, especially for those who are in the first year of transplantation.

Zitieren

APA

Günay, E. (2020). Clinical and safety outcomes of conversion original tacrolimus to generic tacrolimus in Turkish kidney transplant recipients. Transplantation Reports, 5(3), 100056. https://doi.org/10.1016/j.tpr.2020.100056

Vancouver

Günay E. Clinical and safety outcomes of conversion original tacrolimus to generic tacrolimus in Turkish kidney transplant recipients. Transplantation Reports. 2020;5(3):100056. doi:10.1016/j.tpr.2020.100056

BibTeX
@article{Gnay2020,
  author = {Günay, Emrah},
  title = {Clinical and safety outcomes of conversion original tacrolimus to generic tacrolimus in Turkish kidney transplant recipients},
  journal = {Transplantation Reports},
  year = {2020},
  volume = {5},
  number = {3},
  pages = {100056},
  doi = {10.1016/j.tpr.2020.100056}
}
Kostenlos starten →